CEL-SCI Corporation (CVM) |
|
3.5 -0.1 (-2.78%)
|
09-24 16:08 |
|
Open: |
3.51 |
Pre. Close: |
3.6 |
|
High:
|
3.6 |
Low:
|
3.31 |
|
Volume:
|
250,252 |
Market Cap:
|
152(M) |
|
|
|
|
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.61 - 3.63 |
3.63 - 3.65 |
|
Low:
|
3.26 - 3.29 |
3.29 - 3.31 |
|
Close:
|
3.46 - 3.5 |
3.5 - 3.53 |
|
Technical analysis |
as of: 2022-09-23 4:23:17 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.94  One year: 5.6 |
| Support: |
Support1: 3.31 Support2: 2.76 |
| Resistance: |
Resistance1: 4.23 Resistance2: 4.8 |
| Pivot: |
3.93 |
| Moving Average: |
MA(5): 3.6 MA(20): 3.93
MA(100): 3.87  MA(250): 5.82 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.3 %D(3): 10.9 |
| RSI: |
RSI(14): 37.5 |
| 52-week: |
High: 12.81 Low: 2.49 |
| Average Vol(K): |
3-Month: 298 (K) 10-Days: 167 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CVM ] has closed above bottom band by 9.7%. Bollinger Bands are 1.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 23 Sep 2022
Freeville Fiber Festival back to spread wool and cheer - The Ithaca Voice
Thu, 22 Sep 2022
Veterinarians | Veterinary Hospital - hospital.cvm.ncsu.edu
Thu, 22 Sep 2022
Graduate Program | College of Veterinary Medicine - NC State College of Veterinary Medicine
Thu, 22 Sep 2022
Comparative Medicine Institute | College of Veterinary Medicine - NC State College of Veterinary Medicine
Fri, 16 Sep 2022
FDA hindered food program review before it began - Food Safety News
Thu, 15 Sep 2022
CVM launches iLease Electric salary sacrifice scheme - FleetNews
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
43 (M) |
| Shares Float |
41 (M) |
|
% Held by Insiders
|
3.8 (%) |
|
% Held by Institutions
|
38.3 (%) |
|
Shares Short
|
7,910 (K) |
|
Shares Short P.Month
|
8,660 (K) |
Stock Financials |
|
EPS
|
-0.94 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.42 |
|
EPS Est Next Year
|
-0.29 |
|
Book Value (p.s.)
|
1.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-38.9 |
|
Return on Equity (ttm)
|
-96.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.54 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-3.77 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.67 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-8.06 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-06-14 |
|
Ex-Dividend Date
|
1996-08-27 |
|
7 Binary Options
|
|
Your Ad Here
|
|
